NEW YORK (GenomeWeb News) — The European Molecular Biology Laboratory has signed a license for two of Tripos' software platforms for use in its chemical biology research, the company said today.

The agreement covers Tripos' ligand-receptor docking and virtual screening software, the Surflex-Dock, and its Themis software for use in drug discovery research.

EMBL will use the software in research at the Chemical Biological Core Facility, which is a collaboration between EMBL and the German Cancer Research Center in Heidelberg and the University of Heidelberg.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.